Additionally, the MATCH screening trial (targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma, ClinicalTrials.gov identifier: NCT02465060) will investigate the efficacy of MEK and PI3K inhibitors as monotherapies in patients with progressive disease that carries a genetic alteration in either the RAS/MAPK or the PI3K-AKT-mTOR pathways respectively. The gene discussed is PIK3CB; the disease is plasma cell myeloma.